Chapter 1: The evolution of cardiovascular treatment and death rate @Novartis
Chapter 1: The evolution of cardiovascular treatment and death rate  @Novartis
Uploaded March 2022 | Updated November 2026, 3 hours ago
In this video conversation series, Novartis Head of Global Drug Development and Chief Medical Officer Dr John Tsai and cardiologist Dr Steven Nissen discuss their perspectives and experiences around cardiovascular disease, the leading cause of death in the US. In Chapter 1 they speak about the evolution of cardiovascular treatment and death rate.

©2022 Novartis AG
Chapter 1: The evolution of cardiovascular treatment and death rateThe Beacons: Marion’s StoryLiving with neuroendocrine cancer – meet RoyTackling the myths around hiring refugeesStopping coronviruses in their tracksCould predictive analytics help get medicines to patients faster?Sound Up for Lung Cancer: Switching VoicesFirst child-friendly antimalarial 10 year anniversaryWhat does belonging mean to you? Samantha’s storyReimagining clinical trialsEpisode 3: To share or not to share? That is the questionThis is us: Giselle | PRIDE 2022 at Novartis
Novartis |

Chapter 1: The evolution of cardiovascular treatment and death rate

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER